Tables

TABLE 1 PHARMA DRUGS BY SALES' 2017 13
TABLE 2 GLOBAL BIOLOGICS MARKET REVENUE BY REGIONS' 2017-2024 ($MILLION) 49
TABLE 3 OTHER PROMINENT VENDORS OF BIOLOGICS MARKET 59
TABLE 4 F. HOFFMANN-LA ROCHE: OFFERINGS 60
TABLE 5 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 60
TABLE 6 SANOFI.: OFFERINGS 66
TABLE 7 SANOFI: RECENT DEVELOPMENTS 67
TABLE 8 AMGEN INC.: OFFERINGS 73
TABLE 9 AMGEN INC.: RECENT DEVELOPMENTS 74
TABLE 10 NOVO NORDISK A/S: OFFERINGS 81
TABLE 11 NOVO NORDISK A/S: RECENT DEVELOPMENTS 82
TABLE 12 ABBVIE INC.: OFFERINGS 88
TABLE 13 ABBVIE INC: RECENT DEVELOPMENTS 88
TABLE 14 JOHNSON & JOHNSON: PRODUCT OFFERINGS 92
TABLE 15 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 93
TABLE 16 NOVARTIS AG: PRODUCT OFFERINGS 99
TABLE 17 NOVARTIS AG: RECENT DEVELOPMENTS 100
TABLE 18 NOVARTIS AG: OVERVIEW SNAPSHOT 102
TABLE 19 BRISTOL-MYERS SQUIBB: SNAPSHOT 106
TABLE 20 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS 107
TABLE 21 GLAXOSMITHKLINE PLC.: OVERVIEW 108
TABLE 22 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 109
TABLE 23 MERCK & CO: OVERVIEW 110
TABLE 24 MERCK & CO: RECENT DEVELOPMENTS 110
TABLE 25 ELI LILLY AND COMPANY: SNAPSHOT 112
TABLE 26 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS 112
TABLE 27 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW 113
TABLE 28 TEVA PHARMACEUTICAL: RECENT DEVELOPMENTS 113
TABLE 29 ASTRAZENECA PLC: SNAPSHOT 115
TABLE 30 ASTRAZENECA PLC: RECENT DEVELOPMENTS 115
TABLE 31 TAKEDA PHARMACEUTICALS: SNAPSHOT 117
TABLE 32 TAKEDA PHARMACEUTICALS: RECENT DEVELOPMENTS 118

?

LIST OF FIGURE

Charts

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 11
CHART 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS) 12
CHART 3 R&D INVESTMENT BY TOP 10 COMPANIES ($BN) 12
CHART 4 PHARMACEUTICAL DRUGS BY SALES' 2017 14
CHART 5 RESEARCH METHODOLOGY OF GLOBAL BIOLOGICS MARKET 17
CHART 6 GLOBAL BIOLOGICS MARKET REVENUE' 2017-2024 ($MILLION) 21
CHART 7 SEGMENTATION OF GLOBAL BIOLOGICS MARKET 25
CHART 8 PEST ANALYSIS OF GLOBAL BIOLOGICS MARKET 26
CHART 9 PORTER 5 FORCES ON GLOBAL BIOLOGICS MARKET 27
CHART 10 DRO - IMPACT ANALYSIS OF GLOBAL BIOLOGICS MARKET 33
CHART 11 KEY STAKEHOLDERS 35
CHART 12 GLOBAL BIOLOGICS BY PRODUCT SEGMENTATION' 2017 (%) 36
CHART 13 GLOBAL MONOCLONAL ANTOBODY MARKET FORECAST' 2017-2024 ($MILLION) 38
CHART 14 GLOBAL RECOMBINANT PROTEIN/HORMONES MARKET FORECAST' 2017-2024 ($MILLION) 40
CHART 15 GLOBAL VACCINES MARKET FORECAST' 2017-2024 ($MILLION) 41
CHART 16 GLOBAL CELL AND GENE THERAPY MARKET FORECAST' 2017-2024 ($MILLION) 43
CHART 17 GLOBAL CELL AND GENE THERAPY MARKET FORECAST' 2017-2024 ($MILLION) 44
CHART 18 GLOBAL BIOLOGICS MARKET BY APPLICATION SEGMENTATION' 2017 (%) 45
CHART 19 GLOBAL BIOLOGICS MARKET BY GEOGRAPHICAL SEGMENTATION' 2017 (%) 49
CHART 20 BIOLOGICS MARKET REVENUE IN NORTH AMERICA' 2017-2024 ($MILLION) 50
CHART 21 BIOLOGICS MARKET REVENUE IN EUROPE' 2017-2024 ($MILLION) 52
CHART 22 BIOLOGICS MARKET REVENUE IN ASIA PACIFIC' 2017-2024 ($MILLION) 54
CHART 23 BIOLOGICS MARKET REVENUE IN REST OF THE WORLD' 2017-2024 ($MILLION) 56
CHART 24 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT 62
CHART 25 F. HOFFMANN.LA ROCHE: BUSINESS UNITS 63
CHART 26 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE 63
CHART 27 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS 64
CHART 28 SANOFI: OVERVIEW SNAPSHOT 69
CHART 29 SANOFI SA: BUSINESS UNITS 70
CHART 30 SANOFI SA: GEOGRAPHIC PRESENCE 71
CHART 31 SANOFI SA: SWOT ANALYSIS 72
CHART 32 AMGEN INC.: OVERVIEW SNAPSHOT 75
CHART 33 AMGEN INC.: GEOGRAPHIC PRESENCE 77
CHART 34 AMGEN INC: SWOT ANALYSIS 79
CHART 35 NOVO NORDISK: OVERVIEW SNAPSHOT 83
CHART 36 NOVO NORDISK: BUSINESS UNITS 84
CHART 37 NOVO NORDISK: GEOGRAPHIC PRESENCE 85
CHART 38 NOVO NORDISK A/S: SWOT ANALYSIS 86
CHART 39 ABBVIEE INC: OVERVIEW SNAPSHOT 89
CHART 40 ABBVIEE INC.: GEOGRAPHIC PRESENCE 90
CHART 41 ABBVIE INC.: SWOT ANALYSIS 91
CHART 42 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 95
CHART 43 JOHNSON & JOHNSON: BUSINESS UNITS 96
CHART 44 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 96
CHART 45 JOHNSON & JOHNSON: SWOT ANALYSIS 98
CHART 46 NOVARTIS AG: BUSINESS UNITS 102
CHART 47 NOVARTIS AG: GEOGRAPHIC REVENUE 103
CHART 48 NOVARTIS AG: SWOT ANALYSIS 104